Related Experiment Videos
[Vasodilator agents: the lesson from large clinical trials]
N Galiè1, C Magelli, C Rapezzi
1Istituto di Malattie dell'Apparato Cardiovascolare, Università degli Studi, Bologna.
Cardiologia (Rome, Italy)
|December 1, 1993
Summary
Current heart failure treatments offer limited survival benefits and quality of life improvements. New therapeutic strategies are needed to enhance outcomes for patients with left ventricular dysfunction.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Chronic heart failure (CHF) management relies on digoxin and diuretics.
- ACE-inhibitors and isosorbide dinitrate/hydralazine improve survival but with modest gains.
- Asymptomatic left ventricular dysfunction benefits from ACE-inhibitors, yet progression to symptomatic heart failure occurs in some.
Purpose:
- To evaluate novel agents for improving current heart failure therapeutic strategies.
- To address the limitations of existing treatments in prolonging life and enhancing quality of life.
- To explore alternative or adjunctive therapies beyond standard care.
Summary:
- Vasodilator trials in CHF patients showed survival benefits with ACE-inhibitors or isosorbide dinitrate/hydralazine, but with unsatisfactory life extension and minimal quality of life impact.
- ACE-inhibitors slow heart failure progression in asymptomatic patients, but not universally.
- Combining new vasodilators with ACE-inhibitors yielded inconclusive or negative results.
Impact:
- Highlights the need for innovative treatments to improve heart failure patient outcomes.
- Suggests that patient stratification based on clinical, hemodynamic, and neurohormonal profiles may optimize therapeutic resource allocation.
- Emphasizes the limitations of current vasodilator therapies and the search for more effective interventions.